Literature DB >> 18946641

[Prevention and multimodal therapy of hyperthyroidism].

K-D Palitzsch1.   

Abstract

Subclinical and overt hyperthyroidism have been associated with various negative clinical outcomes as for example an increased risk of atrial fibrillation or increased cardiovascular mortality, especially in old age. In order to avoid hyperthyroidism it is strongly recommended not to start any iodine containing drug therapy or to avoid application of contrast agents unless the patient presents with an unremarkable clinical course. TSH suppressive therapy for the treatment of endemic goiter or differentiated low risk thyroid carcinoma is unnecessary, since it favours the development of subclinical hyperthyroidism. Overt hyperthyroidism is treated with antithyroid drugs and/or radioiodine therapy or surgery according to the underlying disease (toxic nodular goiter, Graves' disease).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946641     DOI: 10.1007/s00108-008-2155-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

1.  Minimally invasive video-assisted thyroidectomy: multiinstitutional experience.

Authors:  Paolo Miccoli; Rocco Bellantone; Michel Mourad; Martin Walz; Marco Raffaelli; Piero Berti
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

2.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.

Authors:  P Vitti; T Rago; L Chiovato; S Pallini; F Santini; E Fiore; R Rocchi; E Martino; A Pinchera
Journal:  Thyroid       Date:  1997-06       Impact factor: 6.568

3.  Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.

Authors:  F Azizi; L Ataie; M Hedayati; Y Mehrabi; F Sheikholeslami
Journal:  Eur J Endocrinol       Date:  2005-05       Impact factor: 6.664

4.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

5.  Remission rates with antithyroid drug therapy: continuing influence of iodine intake?

Authors:  B L Solomon; J E Evaul; K D Burman; L Wartofsky
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

6.  The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic.

Authors:  D S Ross; G H Daniels; D Gouveia
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

7.  [The LISA trial-a- randomized, double-blind, placebo-controlled four-arm study of 1,000 patients with nodular goiter in Germany. Study Design and first results of feasibility].

Authors:  Martin Grussendorf; Renate Vaupel; Christoph Reiners; Karl Wegscheider
Journal:  Med Klin (Munich)       Date:  2005-09-15

8.  The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.

Authors:  V Michelangeli; C Poon; J Taft; H Newnham; D Topliss; P Colman
Journal:  Thyroid       Date:  1998-02       Impact factor: 6.568

9.  Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.

Authors:  K Okamura; H Ikenoue; A Shiroozu; K Sato; M Yoshinari; M Fujishima
Journal:  J Clin Endocrinol Metab       Date:  1987-10       Impact factor: 5.958

10.  The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves' disease.

Authors:  Yeşim Erbil; Murat Giriş; Artur Salmaslioglu; Yasemin Ozluk; Umut Barbaros; Burcu Tulumoğlu Yanik; Yersu Kapran; Semra Dogru Abbasoglu; Selcuk Ozarmagan
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

View more
  3 in total

1.  A Prospective Study on Cardiovascular Dysfunction in Patients with Hyperthyroidism and Its Reversal After Surgical Cure.

Authors:  Sankaran Muthukumar; Dhalapathy Sadacharan; Krishnan Ravikumar; Gajarajan Mohanapriya; Zahir Hussain; R V Suresh
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

2.  Frequency of Cardiovascular Manifestation in Patients With Hyperthyroidism.

Authors:  Naresh Kumar Khurana; Suresh Kumar; Sameet Kumar; Pardeep Kumar; Amber Rizwan
Journal:  Cureus       Date:  2021-01-21

3.  Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology.

Authors:  Sibel Ertek; Arrigo F Cicero
Journal:  Arch Med Sci       Date:  2013-11-05       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.